Abivax SA (ABVX):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Abivax SA (ABVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8115)・商品コード:DATA904C8115
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:43
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Abivax SA (Abivax) is a biotechnology company that develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company’s pipeline products include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce functional cure in HIV-patients and inflammatory bowel diseases caused by a dysregulated immune response to host intestinal microflora. Abivax’s ABX544 focuses on the production and purification of neutralizing antibodies from immunized animals with specific antigen for the treatment for EBOLA virus infection. The company also develops various technology platforms including antiviral platform, immune enhancer platform and polyclonal antibody platform. Abivax is headquartered in Paris, France.

Abivax SA (ABVX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Abivax SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Abivax SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Abivax SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Abivax SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Abivax SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Abivax SA, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Evotec and Abivax Enter into Partnership 11
ABIVAX Enters into Co-Marketing Agreement with Finlay Institute 12
Licensing Agreements 13
ExpreS2ion Biotech Enters into Licensing Agreement with Abivax 13
Heber Biotec Enters Into Licensing Agreement with Abivax 14
ABIVAX Enters into Licensing Agreement with CIGB for ABX203 15
Equity Offering 16
Abivax to Raise USD14 Million in Public Offering of Shares 16
Abivax Raises USD65 Million in IPO 17
Debt Offering 18
Abivax to Raise up to USD23.4 Million in Private Placement of Bonds 18
Abivax SA – Key Competitors 19
Abivax SA – Key Employees 20
Abivax SA – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Sep 28, 2018: Abivax first-half 2018 financial results and operations update 22
Mar 16, 2018: ABIVAX: 2017 Full-Year Results and Progress Report 24
Sep 20, 2017: ABIVAX First-Half 2017 Financial Results and Update 28
Mar 15, 2017: ABIVAX Announces 2016 Full-Year Results and Progress Report 31
Corporate Communications 34
Jun 25, 2018: Abivax Names Ian McGowan As Scientific Advisory Board Chair And Juergen Rockstroh As New Member 34
Jan 29, 2018: ABIVAX Names Carol L. Brosgart As Board Director 35
Oct 05, 2017: ABIVAX expands Scientific Advisory Board with appointment of renowned virologist and former President of the Pasteur Institute, Prof. Christian Brechot 36
Government and Public Interest 37
Jan 09, 2017: ABIVAX to receive €8.4 million from Bpifrance “Invest in the Future Program” (PIA) for the development of innovative antiviral drugs 37
Product News 38
10/12/2017: ABIVAX presents novel data on the efficacy of its immune enhancer ABX196 in animal model of liver cancer at the World Vaccine Congress 38
06/12/2017: ABIVAX to Receive €390,000 From Bpifrance for the Development of Its Ebola Hyperimmune Candidate 39
Feb 23, 2017: ABIVAX Has Discovered Novel Antiviral Molecules with Potential for Dengue Virus Treatment 40
Clinical Trials 41
Apr 04, 2017: ABIVAX initiates clinical trial (ABX464-005) to evaluate the effect of ABX464 on HIV-reservoirs in HIV Patients 41
Feb 02, 2017: Phase I Clinical Data of ABX464, ABIVAX’s First-in-Class anti-HIV Drug, Published in Two Articles in Peer-Reviewed Journals 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Abivax SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Abivax SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Abivax SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Abivax SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Abivax SA, Deals By Therapy Area, 2012 to YTD 2018 9
Abivax SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Evotec and Abivax Enter into Partnership 11
ABIVAX Enters into Co-Marketing Agreement with Finlay Institute 12
ExpreS2ion Biotech Enters into Licensing Agreement with Abivax 13
Heber Biotec Enters Into Licensing Agreement with Abivax 14
ABIVAX Enters into Licensing Agreement with CIGB for ABX203 15
Abivax to Raise USD14 Million in Public Offering of Shares 16
Abivax Raises USD65 Million in IPO 17
Abivax to Raise up to USD23.4 Million in Private Placement of Bonds 18
Abivax SA, Key Competitors 19
Abivax SA, Key Employees 20
Abivax SA, Other Locations 21

List of Figures
Abivax SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Abivax SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Abivax SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Abivax SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Abivax SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Abivax SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Abivax SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Abivax SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Abivax SA (ABVX):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8115)販売に関する免責事項を必ずご確認ください。
★調査レポート[Abivax SA (ABVX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆